[{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Y-mAbs Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Agreement","leadProduct":"Naxitamab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Swixx BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Swixx BioPharma \/ Swixx BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Swixx BioPharma \/ Swixx BioPharma"},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"BioCryst Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Berotralstat HCl","moa":"Plasma kallikrein","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Swixx BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Swixx BioPharma \/ Swixx BioPharma","highestDevelopmentStatusID":"15","companyTruncated":"Swixx BioPharma \/ Swixx BioPharma"},{"orgOrder":0,"company":"Swixx BioPharma","sponsor":"Amryt Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Lomitapide","moa":"Microsomal triglyceride transfer protein","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Swixx BioPharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swixx BioPharma \/ Amryt Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Swixx BioPharma \/ Amryt Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Swixx BioPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the terms of the agreement, Swixx will be responsible for commercializing ORLADEYO in 15 markets within CEE. Orladeyo (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of HAE in adult and pediatric patients ...

                          Product Name : Orladeyo

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 23, 2023

                          Lead Product(s) : Berotralstat HCl

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Recipient : BioCryst Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Swixx BioPharma will exclusively distribute DANYELZA to treat patients with relapsed/refractory high-risk neuroblastoma and omburtamab, if approved, for pediatric patients with CNS/leptomeningeal metastasis from neuroblastoma in Eastern Europe, including...

                          Product Name : Danyelza

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          December 18, 2020

                          Lead Product(s) : Naxitamab,Granulocyte-Macrophage Colony-Stimulating Factor

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Recipient : Y-mAbs Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          03

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the agreement, Swixx will distribute Lojuxta® from October 2020 in Albania, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Kosovo, Latvia, Lithuania, Montenegro, North Macedonia, Poland, Romania, Serbia and Slovakia.

                          Product Name : Lojuxta

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 19, 2020

                          Lead Product(s) : Lomitapide

                          Therapeutic Area : Cardiology/Vascular Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Amryt Pharma

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank